Pharma Deals Review, Vol 2009, No 6 (2009)

Font Size:  Small  Medium  Large

ZymoGenetics Licenses Non-Core Assets to Seattle Life Sciences

Taskin Ahmed

Abstract


ZymoGenetics Inc announced the licensing of rights to eight early stage product candidates to Seattle Life Sciences. ZymoGenetics will receive potential milestones and royalties in exchange for licensing rights along with an equity interest in SLS.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.